BeiGene Announces Authorisation of BRUKINSA (zanubrutinib) from the United Kingdom's MHRA for the Treatment of Adults with Waldenström's Macroglobulinemia in Great Britain

Authorisation is based on Phase 3 ASPEN head-to-head trial comparing BRUKINSA against ibrutinib BeiGene (NASDAQ: BGNE; HKEX: 06160) announced today that the United Kingdom (UK) Medicines and Healthcare

Related Keywords

United Kingdom ,China ,Australia ,Japan ,United States ,Canada ,America ,Great Britain ,Robert Mulrooney ,Jane Huang ,Roger Owen ,Emily Collins ,Gabrielle Zhou ,Amgen ,Beigene Ltd ,Regulatory Agency ,Novartis ,Exchange Commission ,James University Hospital Institute Of Oncology ,Bristol Myers Squibb ,Lymphoma Research Foundation ,International Workshop On Waldenstr ,Consultant Haematologist ,James University Hospital Institute ,Chief Medical Officer ,General Manager ,United Kingdom Ireland ,Sixth International Workshop ,Bristol Myers ,Mirati Therapeutics ,North America ,Private Securities Litigation Reform Act ,Accessed December ,Beigene ,Nnounces ,Authorisation ,Brukinsa ,Zanubrutinib ,Rom ,United ,Kingdom ,Phra ,Treatment ,Adults ,Aldenstr 246 M ,Acroglobulinemia ,Treat ,Britain ,